Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only
Information on age, sex, hypertension, diabetes, dyslipidemia, smoking, alcohol intake, depression, anxiety, and sedentariness was collected at baseline
Some brands make unflavored versions, too, which work well in smoothies or other drinks without altering the taste
Conclusions In sum, the findings illustrate that adding bupropion/naltrexone therapy to GLP-1 analog monotherapy results in additional weight loss, even in those with an initially poor response to the monotherapy
In most cases, symptoms can be managed with simple strategies or temporary dose adjustments
You will fumble with the syringe